Thematische Bibliographien / Actinium

Inhaltsverzeichnis

  1. Zeitschriftenartikel
  2. Dissertationen
  3. Bücher
  4. Buchteile
  5. Konferenzberichte
  6. Berichte der Organisationen

Auswahl der wissenschaftlichen Literatur zum Thema „Actinium“

Autor: Grafiati
Veröffentlicht am 4. Juni 2021
Zuletzt aktualisiert am 1. August 2024

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Actinium" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Actinium"

1

WALL, GREG. „ACTINIUM“. Chemical & Engineering News 81, Nr. 36 (08.09.2003): 162. http://dx.doi.org/10.1021/cen-v081n036.p162.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Deblonde, Gauthier J. P., und Rebecca J. Abergel. „Active actinium“. Nature Chemistry 8, Nr. 11 (21.10.2016): 1084. http://dx.doi.org/10.1038/nchem.2653.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Gyurkocza, Boglarka, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R. Litzow, Nebu V. Koshy, Patrick Stiff et al. „Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies“. Blood 138, Supplement 1 (05.11.2021): 1791. http://dx.doi.org/10.1182/blood-2021-148497.

Der volle Inhalt der Quelle
Annotation:
Abstract Background: Several targeted therapies have been recently approved as treatment options for acute myeloid leukemia (AML), however, complete remissions (CR) in relapsed/refractory (R/R) patients remain low. Due to suboptimal responses to standard therapies, most of these patients do not receive an allogeneic hematopoietic cell transplant (HCT). In addition, AML patients ≥55 years have poor tolerance and high morbidity from a myeloablative HCT. The SIERRA trial (Study of Iomab-B in Elderly Relapsed or Refractory AML) has been investigating the use of Iomab-B, an 131I-labeled anti-CD45 monoclonal antibody, to reduce relapse in patients with active, R/R AML who receive HCT as compared to Conventional Care (CC) therapies. With the recent approval of various targeted therapies like BCL-2 inhibitors (e.g., venetoclax), FLT-3 inhibitors (e.g., midostaurin and gilteritinib) and IDH inhibitors (e.g., ivosidenib), the protocol was amended to include patients refractory to these therapies. We are reporting on the success rate of engraftment and tolerability of Iomab-B among the CC patients who cross-over to receive Iomab-B and HCT after failing these agents. Methods: Approximately 150 older patients with R/R AML are to be randomized (1:1) to receive Iomab-B followed by fludarabine, total body irradiation (2 Gy) and allogeneic HCT, or to conventional care (CC). CC patients receive physician's choice of therapy, including targeted therapies, and may proceed to standard of care allogeneic HCT if they achieve CR. CC patients not achieving CR may cross over to Iomab-B-based HCT. Results: Available data for 136 patients (>90% of target enrollment; median age 65) demonstrated they had a median of 3 (range: 1-7) prior lines of AML therapies. Median marrow blast at time of study entry was 25%. Prior to enrollment, 85 (63%) patients received targeted therapies, including BCL-2 inhibitors (62%), FLT-3 inhibitors (18%), IDH inhibitors (7%) and others (13%; e.g., gemtuzumab ozogamicin). Among the 50 evaluable patients in the Iomab-B group that received HCT, all successfully engrafted after a median radiation dose delivered to marrow of 14.7 Gy (range: 4.6 - 44.6) with a median time to neutrophil and platelet engraftment of 14.5 (range: 9-28) and 18 (range: 4-58) days, respectively. Of 63 patients randomized to the CC arm and with data available, 11 (17%) achieved CR and proceeded to standard of care HCT without Iomab-B while 52 (83%) did not respond to CC therapy. Twenty-seven of 63 (43%) CC patients received targeted therapy, of whom 21 received venetoclax with hypomethylating agents (HMA) or low-dose Cytarabine (LDAC). Seven of the 27 (26%) CC patients remission after targeted therapy and received standard of care HCT. Of the 20 patients who did not respond to targeted therapies, 11 (55%) crossed-over and received Iomab-B/HCT with a median radiation dose delivered to marrow of 18 Gy (range: 12.6 - 22.6). Median time to neutrophil and platelet engraftment was 12 (range: 10-27) and 20 (range: 15-38) days, respectively. Safety data are available for 103 transplanted patients in both groups and are presented in table. The incidence of Grade ≥3 febrile neutropenia (FN) was 37% vs 55%, sepsis 5% vs 30%, and mucositis 10% vs 20% in the Iomab-B group compared to all transplanted patients in the CC group. In patients who received targeted therapy and HCT (crossover or standard HCT), incidences of FN, sepsis and mucositis were 39%, 28% and 22%, respectively. Conclusion: SIERRA trial patients not achieving CR with recently approved targeted therapies who then crossed-over to receive HCT with Iomab-B successfully engrafted. Time to engraftment was similar to those who were randomized to receive Iomab-B and HCT. Available data suggest incidences of sepsis and mucositis are lower in the Iomab-B group. (www.sierratrial.com or clinicaltrials.gov NCT02665065) Figure 1 Figure 1. Disclosures Gyurkocza: Actinium Pharmaceutical Inc.: Research Funding. Nath: Actinium: Consultancy, Honoraria; Incyte: Consultancy, Honoraria. Litzow: Amgen: Research Funding; Biosight: Other: Data monitoring committee; Jazz: Other: Advisory Board; Pluristem: Research Funding; Astellas: Research Funding; Actinium: Research Funding; Omeros: Other: Advisory Board; AbbVie: Research Funding. Koshy: Astellas; Actinium Pharmaceuticals: Other: Principal Investigator, SIERRA Trial, Actinium, Speakers Bureau. Stiff: Seagen: Research Funding; Incyte: Research Funding; Gamida Cell: Research Funding; Janssen: Research Funding; CRISPR Therapeutics: Consultancy, Honoraria; Kite, a Gilead Company: Research Funding; Macrogenics: Research Funding; Bristol Myers Squibb: Research Funding; Cellectar: Research Funding; BioLineRX: Research Funding; MorphoSys: Consultancy, Honoraria; Amgen: Research Funding; Karyopharm: Consultancy, Honoraria; Cellectar: Research Funding; Actinium: Research Funding. Abhyankar: Incyte/Therakos: Consultancy, Research Funding, Speakers Bureau. Hari: Karyopharm: Consultancy; Millenium: Membership on an entity's Board of Directors or advisory committees, Research Funding; Adaptive Biotech: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Oncopeptides: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Celgene-BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other, Research Funding, Speakers Bureau. Chen: Actinium Pharmaceuticals: Other: Principal Investigator, SIERRA Trial, Actinium. Sabloff: Novartis: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; TaiHo: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Astellas: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Jaxx: Membership on an entity's Board of Directors or advisory committees; ROCHE: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees. Orozco: Actinium Pharmaceuticals: Other: Principal Investigator, SIERRA Trial, Actinium, Research Funding. Foran: abbvie: Research Funding; revolution medicine: Honoraria; novartis: Honoraria; certara: Honoraria; actinium: Research Funding; OncLive: Honoraria; aptose: Research Funding; trillium: Research Funding; gamida: Honoraria; takeda: Research Funding; boehringer ingelheim: Research Funding; bms: Honoraria; taiho: Honoraria; syros: Honoraria; sanofi aventis: Honoraria; pfizer: Honoraria; servier: Honoraria; kura: Research Funding; h3bioscience: Research Funding; aprea: Research Funding; sellas: Research Funding; stemline: Research Funding. Jamieson: Actinium Pharmaceuticals: Other: Principal Investigator, SIERRA Trial, Actinium. Magalhaes-Silverman: Actinium Pharmaceuticals; Incyte; Marker Therapeutics: Other: Principal Investigator, SIERRA Trial, Actinium, Research Funding. Schuster: Takeda: Consultancy, Speakers Bureau; MorphoSys Ag: Consultancy, Speakers Bureau; Astellas: Consultancy, Speakers Bureau; Intellisphere: Consultancy, Speakers Bureau; AbbVie Incorporated: Consultancy, Speakers Bureau; Pharmacyclics: Consultancy, Research Funding, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Epizyme: Consultancy, Speakers Bureau; Bristol Myers Squibb: Consultancy, Speakers Bureau; BeiGene: Consultancy, Speakers Bureau; Actinium Pharmaceuticals: Other: Principal Investigator, SIERRA Trial, Actinium Pharmaceuticals, Research Funding; Rafael Pharmaceuticals: Research Funding; GSK: Research Funding; AlloVir: Research Funding; Incyte: Research Funding; Seattle Genetics: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; Genentech: Consultancy, Speakers Bureau; Amgen: Consultancy, Current equity holder in publicly-traded company, Speakers Bureau; Celgene: Consultancy, Current equity holder in publicly-traded company, Speakers Bureau. Law: Actinium Pharmaceuticals: Research Funding; Novartis: Consultancy. Levy: Takeda, Celgene, Seattle Genetics, AbbVie, Jazz Pharmaceuticals, Gilead Sciences, Bristol-Myers Squibb, Amgen, Spectrum Pharmaceuticals,Janssen.: Consultancy. Lazarus: Bristol Myer Squibb: Membership on an entity's Board of Directors or advisory committees. Giralt: PFIZER: Membership on an entity's Board of Directors or advisory committees; AMGEN: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; SANOFI: Membership on an entity's Board of Directors or advisory committees; CELGENE: Membership on an entity's Board of Directors or advisory committees; JAZZ: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; JENSENN: Membership on an entity's Board of Directors or advisory committees; Actinnum: Membership on an entity's Board of Directors or advisory committees. Berger: Actinium Pharmaceuticals, Inc: Current Employment. Spross: Actinium Pharmaceuticals: Current Employment, Current holder of stock options in a privately-held company. Desai: Actinium Pharmaceuticals: Current Employment, Current holder of stock options in a privately-held company. Reddy: Actinium Pharmaceuticals: Current Employment, Current holder of stock options in a privately-held company. Pagel: AstraZeneca: Consultancy; MEI Pharma: Consultancy; Epizyme: Consultancy; Actinium Pharmaceuticals: Consultancy; Kite, a Gilead Company: Consultancy; BeiGene: Consultancy; Pharmacyclics/AbbVie: Consultancy; Gilead: Consultancy; Incyte/MorphoSys: Consultancy.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Eliav, Ephraim, Sergei Shmulyian, Uzi Kaldor und Yasuyuki Ishikawa. „Transition energies of lanthanum, actinium, and eka-actinium (element 121)“. Journal of Chemical Physics 109, Nr. 10 (08.09.1998): 3954–58. http://dx.doi.org/10.1063/1.476995.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Yushchenko, V., V. Gopka, A. V. Yushchenko, A. Shavrina, Ya Pavlenkо und S. Vasil’eva. „ACTINIUM ABUNDANCES IN STELLAR ATMOSPHERES“. Odessa Astronomical Publications 34 (03.12.2021): 70–73. http://dx.doi.org/10.18524/1810-4215.2021.34.244288.

Der volle Inhalt der Quelle
Annotation:
This paper presents a study of radioactive actinium in the atmospheres of stars located in galaxies with different chemical evolution history – namely, Przybylski's Star (HD 101065) in the Milky Way and the red supergiant PMMR27 in the Small Magellanic Cloud; it also reports the findings of the previous research of the red supergiant RM 1-667 in the Large Magellanic Cloud and the red giant BL138 in the Fornax dwarf spheroidal galaxy. The actinium abundance is close to that of uranium in the atmospheres of certain stars in the Milky Way’s halo and in the atmosphere of Arcturus. The following actinium abundances have been obtained (in a scale of lg N(H) = 12): for the red supergiants PMMR27 and RM 1- 667 lg N(Ac) = -1.7 and lg N(Ac) = -1.3, respectively, and for the red giant BL138 lg N(Ac) = -1.6. The actinium abundance in the atmosphere of Przybylski's Star (HD 101065) is lg N(Ac) = `0.94±0.09, which is more than two orders of magnitude higher than those in the atmospheres of the other studied stars.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Durrani, Matin. „From actinium to zinc“. Physics World 32, Nr. 8 (August 2019): 50. http://dx.doi.org/10.1088/2058-7058/32/8/39.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Zielińska, B., und A. Bilewicz. „The hydrolysis of actinium“. Journal of Radioanalytical and Nuclear Chemistry 261, Nr. 1 (2004): 195–98. http://dx.doi.org/10.1023/b:jrnc.0000030956.61947.c5.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Tsoupko-Sitnikov, V., Yu Norseev und V. Khalkin. „Generator of actinium-225“. Journal of Radioanalytical and Nuclear Chemistry Articles 205, Nr. 1 (April 1996): 75–83. http://dx.doi.org/10.1007/bf02040552.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Pratiwi, Anita Puji, Trapsilo Prihandono und Sri Handono Budi Prastowo. „Numerical Solution of Radioactive Core Decay Activity Rate of Actinium Series Using Matrix Algebra Method“. Jurnal Penelitian Pendidikan IPA 7, Nr. 3 (07.07.2021): 395. http://dx.doi.org/10.29303/jppipa.v7i3.716.

Der volle Inhalt der Quelle
Annotation:
The Actinium 235 series is one of the radioactive series which is widely used as a raw material for reactors and nuclear activities. The existence of this series is found in several countries such as West USA, Canada, Australia, South Africa, Russia, and Zaire. The purpose of this study was to determine the activity value and the number of radioactive nucleus decay atoms on the actinium 235 rendered in a very long decay time of 4.3 x 109 years. The decay count in this study uses an algebraic matrix method to simplify the chain decay solution, which generally uses the concept of differential equations. The solution using this method can be computationally simulated using the Matlab program. This study indicates that the value of the decay activity experienced by each element in this series is the same, which is equal to 2,636 x 1011 Bq. This condition causes the actinium 235 series to experience secular equilibrium because the half-life of the parent nuclide is greater than the nuclide derivatives. The decay activity of the radioactive nucleus under the actinium 235 series is strongly influenced by the half-life of the nuclides, the decay constants, and the number of atoms after decay
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Hoffman, Darleane C. „Glenn Theodore Seaborg. 19 April 1912 — 25 February 1999“. Biographical Memoirs of Fellows of the Royal Society 53 (Januar 2007): 327–38. http://dx.doi.org/10.1098/rsbm.2007.0021.

Der volle Inhalt der Quelle
Annotation:
Glenn T. Seaborg was a world-renowned nuclear chemist, educator, scientific adviser to ten US presidents, humanitarian, and Nobel laureate in chemistry. He is probably best known for his leadership of the team that in 1941 accomplished the first chemical separation and positive identification of plutonium and for his ‘revolutionary’ actinide concept in which he placed the first 14 elements heavier than actinium in the periodic table of elements as a 5f transition series under the lanthanide 4f transition series. He went on to be co-discoverer of nine elements beyond plutonium, culminating in 1974 in the production of element 106, later named seaborgium in his honour.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Dissertationen zum Thema "Actinium"

1

Waldek, Achim Marcus. „Bestimmung der Ionisationsenergie von Actinium und Ultraspurenanalyse von Plutonium mit resonanter Ionisationsmassenspektrometrie (RIMS)“. [S.l. : s.n.], 2000. http://ArchiMeD.uni-mainz.de/pub/2001/0071/diss.pdf.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Niese, Siegfried. „Discovery of actinium and the thorium isotope 230Th“. Siegfried Niese, 2017. https://slub.qucosa.de/id/qucosa%3A7825.

Der volle Inhalt der Quelle
Annotation:
In 1902 Friedrich Giesel has discovered after co-precipitation with lanthanum from samples obtained by chemical treatment of uranium minerals a new radioactive element. Because of its emanating properties he named it emanium, which we now know as actinium. In 1899 André-Louis Debierne found a radioactive substance with chemical properties of titanium, and after further investigations in 1900 of thorium. Because of its high activity he explained it as a new element and named it actinium. It mainly consisted of 230Th. In 1904 he explained that his actinium was identical with the emanium found by Giesel. He had taken over the discovery of Giesel and had rejected his own one, because he had been afraid that his discovered substance which he could not separate from thorium would not be accepted as a new chemical element. In 1909 Boltwood looked for the long-lived precursor of radium. He isolated according to the procedure of Debierne the thorium fraction from the pitchblende and after some time he found in it radium but not in emanium produced according the procedure of Giesel. Boltwood named the mother-element of radium ionium, which was first accepted as a new radioactive element and later identified as thorium isotope 230Th. Although Debierne has discovered and later rejected this substance for a long time he was accepted as discoverer of actinium.
Entdeckung des Actiniums und des Thoriumisotopes 230Th Im Jahr 1902 entdeckte Friedrich Giesel nach Mitfällung von Lanthan aus Proben der chemischen Behandlung von Uranmineralen ein neues radioaktives Element, das er wegen seiner starken Bildung von Emanation Emanium nannte und mit dem jetzt als Actinium bezeichneten Element identisch ist.1899 fand André-Louis Debierne in Pechblende eine dem Titan chemisch ähnliche radioaktive Substanz, der er 1900 eine größere Ähnlichkeit mit dem Thorium zuschrieb. Wegen seiner hohen Radioaktivität erklärte er sie für ein neues Element und nannte es Actinium. Es bestand hauptsächlich aus 230Th. 1904 erklärte er, dass sein Actinium mit dem von Giesel entdeckten dem Lanthan ähnlichen Emanium identisch sei. Er übernahm Giesels Entdeckung und verwarf seine eigene, weil er fürchtete, dass seine entdeckte Substanz, die er nicht vom Thorium trennen konnte, nicht als neues chemisches Element anerkannt werden würde. Als Bertran Boltwood1909 nach den langlebigen Vorgängerelement von Radium suchte, trennte er nach der Vorschrift von Debierne die Thoriumfraktion aus der Pechblende ab und stellte fest, dass sich daraus mit der Zeit Radium gebildet hatte, wogegen sich aus dem nach der Vorschrift von Giesel abgetrennten Emanium kein Radium gebildet hatte. Boltwod nannte das Vorgängerelement von Radium Ionium, das zuerst als neues radioaktives Element anerkannt und entspäter als Thoriumisotop 230Th identifiziert wurde. Trotzdem Debierne nicht Actinium sondern diese Substanz entdeckt und später verworfen hatte, war er lange Zeit als Entdecker des Actiniums anerkannt.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Niese, Siegfried. „Die Entdeckung des Actiniums“. Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-152864.

Der volle Inhalt der Quelle
Annotation:
Friedrich Giesel entdeckte im Jahre 1902 das Actinium nach Fällung mit Lanthan aus einer Pechblendelösung. Er hatte den Namen Emanium vorgeschlagen, da es stark emanierte. Lange Zeit wurde nur Andre-Louis Debierne als Entdecker des Actiniums akzeptiert, da er 1904 behauptet hatte, dass die von ihm im Jahr 1900 gefundene von ihm Actinium genannte radioaktive Substanz mit den chemischen Eigenschaften des Thoriums, die hauptsächlich das Thoriumisotop 230Th enthielt, mit dem Emanium von Giesel identisch gewesen sei. In dem Beitrag werden die Entdeckungen von Debierne und Giesel und der Weg bis zur Anerkennung von Giesel als Entdecker vorgestellt
Friedrich Giesel discovered actinium in 1902 after co precipitation with lanthanum from a solution of pitchblende. He had suggested to name it emanium, because of its emanating properties. But for a long time only Andre-Louis Debierne was accepted as discoverer of actinium, because in 1904 he has explained, that the radioactive substance found by him in 1900, with chemical properties of thorium, named actinium, and mainly consisting of the thorium isotope 230Th, has been identical with the emanium of Giesel. The discoveries of Giesel and Debierne are explained as well as the steps on the way of acceptance of Giesel as discoverer of actinium
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Geibert, Walter. „Actinium-227 als Tracer für Advektion und Mischung in der Tiefsee = Actinium-227 as a tracer for advection and mixing in the deep-sea /“. Bremerhaven : Alfred-Wegener-Institut für Polar- und Meeresforschung, 2001. http://www.awi-bremerhaven.de/GEO/Publ/PhDs/WGeibert.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Niese, Siegfried. „Die Entdeckung des Actiniums“. Gesellschaft Deutscher Chemiker, 2013. https://slub.qucosa.de/id/qucosa%3A4674.

Der volle Inhalt der Quelle
Annotation:
Friedrich Giesel entdeckte im Jahre 1902 das Actinium nach Fällung mit Lanthan aus einer Pechblendelösung. Er hatte den Namen Emanium vorgeschlagen, da es stark emanierte. Lange Zeit wurde nur Andre-Louis Debierne als Entdecker des Actiniums akzeptiert, da er 1904 behauptet hatte, dass die von ihm im Jahr 1900 gefundene von ihm Actinium genannte radioaktive Substanz mit den chemischen Eigenschaften des Thoriums, die hauptsächlich das Thoriumisotop 230Th enthielt, mit dem Emanium von Giesel identisch gewesen sei. In dem Beitrag werden die Entdeckungen von Debierne und Giesel und der Weg bis zur Anerkennung von Giesel als Entdecker vorgestellt.
Friedrich Giesel discovered actinium in 1902 after co precipitation with lanthanum from a solution of pitchblende. He had suggested to name it emanium, because of its emanating properties. But for a long time only Andre-Louis Debierne was accepted as discoverer of actinium, because in 1904 he has explained, that the radioactive substance found by him in 1900, with chemical properties of thorium, named actinium, and mainly consisting of the thorium isotope 230Th, has been identical with the emanium of Giesel. The discoveries of Giesel and Debierne are explained as well as the steps on the way of acceptance of Giesel as discoverer of actinium.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Bray, Travis Henry Albrecht-Schmitt Thomas E. „Crossroads and terminations in transuranium chemistry“. Auburn, Ala, 2008. http://repo.lib.auburn.edu/EtdRoot/2008/SUMMER/Chemistry_and_Biochemistry/Dissertation/Bray_Travis_43.pdf.

Der volle Inhalt der Quelle
Annotation:
Thesis (Ph. D.)--Auburn University, 2008.
Abstract. Vita. Parts of this dissertation have been published as: Na₂[UO₂(IO₃)₄(H₂O)] (Ch. 2: Bray, T.H.; et al., Inorg. Chem., 2006, 45, 8251-8257.), An(IO₃)₄(An = Np, Pu) and Np(IO₃)₄·nH2O (Ch. 3: Bray, T.H.; et al., Inorg. Chem., 2007, 46, 3663-3668.), Pu(SeO₃)₂ (Ch. 4: Bray, T.H.; et al., J. Solid State Chem., 2008, 181, 493-498.), NpFPO₄ and Cs₂Np₂F₇PO₄ (Ch. 5: Bray, T.H.; et al., J. Solid State Chem., 2007, 180, 70-74.), [C₆H₁₄N₂][(UO₂)₄(HPO₄)₂PO₄)₂(H₂O)]·H₂O (Ch. 6: Bray, T.H.; et al., "Synthesis and Structure of [C6H14N2][(UO2)4(HPO4)2(PO4)2(H2O)]·H₂O: An Expanded Open-Framework Amine-Bearing Uranyl Phosphate," In press: Journal of Solid State Chemistry April 24, 2008.), and Np(CH₃PO₃)(CH₃PO₃H)(NO₃)(H₂O)·H₂O (Ch. 7: Bray, T.H.; et al., Inorg. Chem., 2007, 46, 10959-10961.). Includes bibliographical references.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

VanSant, Paul Daniel. „Medical Isotope Production of Actinium 225 By Linear Accelerator Photon Irradiation of Radium 226“. Thesis, Virginia Tech, 2013. http://hdl.handle.net/10919/50984.

Der volle Inhalt der Quelle
Annotation:
There is a present and future need for the medical isotope Actinium-225, currently in short supply worldwide.  Only a couple manufacturers produce it in very low quantities.  In roughly the past 10 years the medical community has explored the use of Ac-225 and its daughter Bismuth-213 for targeting a number of differing cancers by way of Targeted Alpha Therapy (TAT). This method utilizes the alpha-decay of both Ac-225 (half-life 10 days) and Bi-213
(half-life 46 min) to kill cancerous cells on a localized basis.  Maximum energy is delivered to the cancer cells thereby greatly minimizing healthy tissue damage.  
This research proposes a production method using a high-energy photon spectrum (generated by a linear accelerator or LINAC) to irradiate a sample of Radium-226 (half-life 1600yrs).  The photo-neutron reaction liberates neutrons from Ra-226 atoms leaving behind Radium-225 (half-life 14.7 days).  Ra-225 decays naturally through beta emission to Ac-225.  Previous research demonstrated it is possible to produce Ac-225 using a LINAC; however, very low yields resulted which questioned the feasibility of this production method.  This research proposes a number of LINAC and radium sample modifications that could be greatly increase yield amounts for practical use.  
Additionally, photo-neutron cross-section data for Ra-226 was used, which led to improved yield calculations for Ra-225.  A MATLAB® model was also created, which enables users to perform quick yield estimates given several key model parameter inputs.  Obtaining a sufficient supply of radium material is also of critical importance to this research.  Therefore information was gathered regarding availability and inventory of Radium-226.  This production method would serve as a way to not only eliminate many hazardous radium sources destined for interim storage, but provide a substantial supply of Ac-225 for future cancer treatment.

Master of Science
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Melville, Graeme P. „Production of AC-225 for cancer therapy by photon induced transmutation of RA-226“. Thesis, View thesis, 2007. http://handle.uws.edu.au:8081/1959.7/18860.

Der volle Inhalt der Quelle
Annotation:
Radium needles that were once implanted into tumours as a cancer treatment are now obsolete and constitute a radioactive waste problem, as their half-life is 1600 years. The reduction of radium by photonuclear transmutation by bombarding Ra-226 with high-energy photons from a medical linac has been investigated. The irradiated needles would then be processed to remove the Ac-225, which can then be used for .Targeted Alpha Therapy. (TAT) of cancer. This project has the potential to slowly reduce obsolete radioactive material, and displace future expensive importation of Ac-225 from Russia, Germany (Institute for Transuranium Elements - ITU) and the US in the years ahead. This thesis progresses through a number of stages and begins by providing a background to the usefulness of Ac-225 as an alpha emitter, some of the equipment used in the experimental work such as linear accelerators and detectors, as well as the initialisation of a process whereby a reliable source of high-grade radium is secured, suitable equipment obtained, followed by a series of experiments leading to the production of the desired product, actinium and bismuth. The second stage of this study involved the formulation of a theoretical model in which the bremsstrahlung photon spectrum at 18 MV linac electron energy is convoluted with the corresponding photonuclear cross sections of Ra- 226. This enabled the total integrated yield of Ra-225 and its daughter product Ac-225 to be obtained. The third stage of this study ties the theoretical and experimental work together by presenting the results of a number of experiments performed on radium sources. These experiments were performed over a period of about three years using a variety of detectors in a hospital setting. These experiments, as presented in this thesis, demonstrate that Ac-225 can be produced in small quantities by a medical linac or in commercial quantities by the use of a high-powered linac or cyclotron, thereby, ensuring a reliable supply of Ra-225 for TAT and also reducing the radium waste product.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Moulin, Jeanne. „Comportement des radionucléides des familles de l'uranium dans les eaux superficielles du site de la Crouzille, Limousin : implications géochimiques“. Châtenay-Malabry, Ecole centrale de Paris, 2008. http://www.theses.fr/2008ECAP1099.

Der volle Inhalt der Quelle
Annotation:
La compréhension du comportement des radionucléides naturels en milieu continental est importante pour pouvoir mener à bien la réhabilitation d’un site minier uranifère et préserver la qualité de l’eau. L’objectif de cette thèse est à la fois de déterminer la source d’apports de radionucléides dans une réserve d’eau potable et d’améliorer la connaissance du comportement des radionucléides des familles de l’uranium, en particulier de l’actinium. Le site d’étude retenu se situe à proximité d’un site minier réhabilité et permet d’étudier le transport des radionucléides dans les eaux superficielles (ruisseaux) mais aussi leur rétention : influence de la matière organique des tourbières sur les radionucléides et intérêt d’une retenue d’eau. Grâce à des ultrafiltrations tangentielles, la distribution des radionucléides dans les phases particulaire, colloïdale et dissoute est déterminée. Les importants volumes d’eau permettent d’utiliser la spectrométrie gamma comme méthode de mesure. Cette méthode permet de mesurer presque tous les radionucléides naturels en seulement deux comptages. Cependant, la faible activité des radioéléments de la famille du 235U impose l’utilisation de spectromètres gamma à ultra-bas bruit de fond, comme ceux du Laboratoire Souterrain de Modane. Cette étude a tout d’abord permis de montrer que la tourbière des Sagnes ne relargue que pas ou peu de radionucléides dans le ruisseau des Sagnes, comme c’est le cas pour les autres tourbières du monde bien qu’elle soit plus marquée. Dans un deuxième temps, elle a apporté des précisions sur le comportement des radionucléides des familles de l’uranium dans les eaux superficielles
Understanding natural radionuclides behaviour in surface water is a required step to achieve uranium mine rehabilitation and preserve water quality. The first objective of this thesis is to determine which are the radionuclides sources in a drinking water reservoir. The second objective is to improve the knowledge about the behaviour of uranium series radionuclides, especially actinium. The investigated site is a brook (Sagnes, Limousin, France) which floods a peat bog contaminated by a former uranium mine and which empties into the Crouzille lake. It allows studying radionuclides transport in surface water and radionuclides retention through organic substance or water reservoir. Radionuclides distribution in particulate, colloidal and dissolved phases is determined thanks to ultrafiltrations. Gamma spectrometry allows measuring almost all natural radionuclides with only two counting stages. However, low activities of 235U serie radionuclides impose the use of very low background well-type Ge detectors, such as those of the Underground Laboratory of Modane (France). Firstly, this study shows that no or few radionuclides are released by the Sagnes peat bog, although its radioactivity is important. Secondly, it provides details on the behaviour of uranium series radionuclides in surface water. More specifically, it provides the first indications of actinium solubility in surface water. Actinium’s behaviour is very close to uranium’s even if it is a little less soluble
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Levier, Martin. „Développement et utilisation de l'Actinium-227 comme traceur du mélange de l'océan profond“. Electronic Thesis or Diss., université Paris-Saclay, 2022. http://www.theses.fr/2022UPASJ006.

Der volle Inhalt der Quelle
Annotation:
Le mélange vertical dans l'océan profond est un processus important pour le fonctionnement de la circulation thermohaline océanique et donc pour le système climatique global. L'actinium-227 (227Ac) est un isotope radioactif naturel produit par désintégration du protactinium-231 (231Pa) dans les sédiments marins profonds. Comme il est soluble, il diffuse dans les eaux de fond. Sa demi-vie courte (22 ans) en fait un traceur spécifique du mélange vertical dans l'océan profond. L'analyse de 227Ac par comptage nucléaire utilisé jusqu'à maintenant nécessite de 50 à plusieurs centaines de litres d'eau et reste malgré tout peu précises. Ceci a limité l'utilisation du 227Ac en océanographie. Au cours de cette thèse, nous avons développé un protocole commun de séparation et d'analyse de 227Ac et 231Pa par MC-ICPMS à partir de 10L d'eau de mer. En plus de ces deux isotopes, ce protocole de séparation produit différentes fractions pouvant permettre d'analyser d'autres traceurs (isotopes du Nd, Ra ou Th) sur un même échantillon d'eau.Ce protocole a été appliqué à des échantillons d'archives prélevés lors de la campagne Bonus GoodHope, dans le secteur Atlantique de l'océan Austral. Le 231Pa a été analysé en parallèle du 227Ac, dont l'analyse est primordiale pour exploiter les données de 227Ac . Ces nouvelles données de 231Pa ont conforté la théorie de sa forte affinité pour l'opale produite par les diatomées et a permis d'affiner le modèle de transport des radionucléides le long des isopycnes remontant au sud de l'ACC. Les résultats obtenus de 227Ac ont permis d'estimer des coefficients de mélange turbulent de 1 cm2/s au-dessus de la dorsale océanique, de 14 cm2/s à cause d'une turbulence accrue près de la marge africaine et de l'ordre de 30 cm2/s dans le gyre de Weddell. Une application de ces valeurs est notamment proposée pour décrire la distribution de la concentration et de la signature isotopique du Nd, à l'aide d'un modèle prenant en compte les processus près de la marge continentale
The vertical mixing in the deep ocean is an important process for the functioning of thermohaline circulation and also for the global climatic system. L'actinium-227 (227Ac) is a natural radioactive isotope product by the protactinium-231 (231Pa) decay in deep marine sediment. The short half-life of this isotope (22 years) makes it a specific tracer of vertical mixing of deep ocean. 227Ac analysis by nuclear counting used until now required from 50 to several hundred liters of water for a limited accuracy. This limited strongly the use of 227Ac in oceanography until today. During this thesis, we developed a join 231Pa-227Ac purification protocol suitable for 10L seawater sample, to perform analysis by MC-ICPMS. In addition to these two isotopes, this separation protocol provides different fractions that can be used to other tracers (Nd, Ra or Th isotopes) from the same water sample.This protocol was applied to archival samples collected during the Bonus GoodHope cruise, in the Southern Ocean. 231Pa was measured at the same time as 227Ac because its analysis is essential to exploit 227Ac data. These new 231Pa data support the previous hypothesis of a strong affinity toward the opal produced by the diatoms and allow to refine the transport of radionuclides along slopping isopycnal surfaces at the South of the ACC. Results from 227Ac data gave estimates of the vertical eddy diffusion coefficient of 1 cm2/s over the mid-ocean ridge, of 14 cm2/s near the African margin due to an enhanced turbulence and of the order of 30 cm2/s in the Weddell gyre. An application of these values is proposed to describe the concentration and isotopic signature distributions of Nd near the continental margin
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Bücher zum Thema "Actinium"

1

1949-, Meyer G., und Morss Lester R, Hrsg. Synthesis of lanthanide and actinide compounds. Dordrecht: Kluwer Academic, 1991.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Topical, Conference on Plutonium and Actinides (6th 2010 Keystone Colo ). Plutonium futures-- the science 2010: [Topical Conference on Plutonium and Actinides] , Keystone, Colorado, September 19-23, 2010. LaGrange Park, Ill: American Nuclear Society, 2010.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Agency, International Atomic Energy, Hrsg. Decay data of the transactinium nuclides. Vienna: International Atomic Energy Agency, 1986.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Zuev, V. A. Geksaftoridy aktinoidov. Moskva: Ėnergoatomizdat, 1991.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

J, Marks Tobin, Fragalà Ignazio L. 1943- und North Atlantic Treaty Organization. Scientific Affairs Division., Hrsg. Fundamental and technological aspects of organo-f-element chemistry. Dordrecht: D. Reidel Pub. Co., 1985.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Geibert, Walter. Actinium-227 als Tracer für Advektion und Mischung in der Tiefsee =: Actinium-227 as a tracer for advection and mixing in the deep-sea. Bremerhaven: Alfred-Wegener-Institut für Polar- und Meeresforschung, 2001.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

1927-, Kasuya T., Hrsg. Physical properties of actinide and rare earth compounds: Search for heavy fermion characters. Tokyo, Japan: Publication Office, Japanese Journal of Applied Physics, 1993.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Wijn, H. P. J., Hrsg. Actinide Monochalcogenides. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-47043-4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Healey, David. Actinic light. Sutton Coldfield, West Midlands, United Kingdom: The Blackford Press, 2012.

Den vollen Inhalt der Quelle finden
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Kalmykov, Stepan N., und Melissa A. Denecke, Hrsg. Actinide Nanoparticle Research. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-11432-8.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Mehr Quellen

Buchteile zum Thema "Actinium"

1

Kirby, H. W. „Actinium“. In The Chemistry of the Actinide Elements, 14–40. Dordrecht: Springer Netherlands, 1986. http://dx.doi.org/10.1007/978-94-009-4077-2_2.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Kirby, H. W., und Lester R. Morss. „Actinium“. In The Chemistry of the Actinide and Transactinide Elements, 18–51. Dordrecht: Springer Netherlands, 2010. http://dx.doi.org/10.1007/978-94-007-0211-0_2.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Turova, Nataliya. „Scandium, Actinium“. In Inorganic Chemistry in Tables, 77. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-20487-6_26.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Predel, B. „Ac-Ag (Actinium - Silver)“. In Ac-Ag ... Au-Zr, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2006. http://dx.doi.org/10.1007/10793176_3.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Predel, B. „Ac-Au (Actinium - Gold)“. In Ac-Ag ... Au-Zr, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2006. http://dx.doi.org/10.1007/10793176_4.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Predel, B. „Ac-B (Actinium - Boron)“. In Ac-Ag ... Au-Zr, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2006. http://dx.doi.org/10.1007/10793176_5.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Predel, B. „Ac-Cr (Actinium - Chromium)“. In Ac-Ag ... Au-Zr, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2006. http://dx.doi.org/10.1007/10793176_6.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Predel, B. „Ac-Cu (Actinium - Copper)“. In Ac-Ag ... Au-Zr, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2006. http://dx.doi.org/10.1007/10793176_7.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Predel, B. „Ac-H (Actinium - Hydrogen)“. In Ac-Ag ... Au-Zr, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2006. http://dx.doi.org/10.1007/10793176_8.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Predel, B. „Ac-Hg (Actinium - Mercury)“. In Ac-Ag ... Au-Zr, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2006. http://dx.doi.org/10.1007/10793176_9.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "Actinium"

1

Reissig, F., K. Zarschler, Z. Novy, M. Petrik, H. J. Pietzsch, K. Kopka und C. Mamat. „Entwicklung alternativer Verbindungen für die PSMA-Therapie mit Actinium-225“. In 61. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin. Georg Thieme Verlag, 2023. http://dx.doi.org/10.1055/s-0043-1766331.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Rosenbusch, M., Y. Ito, P. Schury, M. Wada, S. Ishizawa, S. Kimura, H. Miyatake, T. Niwase und H. Wollnik. „Multiple-fit Analysis of Neutron-Deficient Radium and Actinium Isotopes“. In Proceedings of 10th International Conference on Nuclear Physics at Storage Rings (STORI’17). Journal of the Physical Society of Japan, 2021. http://dx.doi.org/10.7566/jpscp.35.011004.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Kovatsch, Matthias, Martin Lanter und Simon Duquennoy. „Actinium: A RESTful runtime container for scriptable Internet of Things applications“. In 2012 3rd International Conference on the Internet of Things (IOT). IEEE, 2012. http://dx.doi.org/10.1109/iot.2012.6402315.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Feuerecker, B., A. Gafita, R. Tauber, CD Alessandria, C. Seidl, F. Bruchertseifer, M. Retz, W. Weber, A. Morgenstern und M. Eiber. „Effekte eines Zyklus Actinium-225-PSMA-617 (AcPSMA) auf die Speicheldrüsen-vorläufige Ergebnisse“. In NuklearMedizin 2020. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1708336.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Zhu, Z., D. Luo, B. Wollenberg, B. Feuerecker, M. Eiber und A. Pickhard. „Treatment of PSMA-255-Actinium therapy induced xerostomia in patients with prostate cancer“. In Abstract- und Posterband – 91. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Welche Qualität macht den Unterschied. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1710928.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

HARVEY, JAMES, JERRY A. NOLEN, THOMAS KROC, ITACIL GOMES, E. PHILIP HORWITZ und DANIEL R. MCALISTER. „PRODUCTION OF ACTINIUM-225 VIA HIGH ENERGY PROTON INDUCED SPALLATION OF THORIUM-232“. In Proceedings of the Workshop. WORLD SCIENTIFIC, 2010. http://dx.doi.org/10.1142/9789814317290_0044.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Bergmann, R., C. Arndt, D. Máthé, N. Berndt, LR Loureiro, N. Kovács, D. Szöllösi et al. „Copper-64/Actinium-225-human anti-PSCA-IgG4 theranostics of a prostate cancer model“. In NuklearMedizin 2021 – digital. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1726705.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Mirsaidov, U., Kh M. Nazarov, B. D. Boboev und E. Yu Malysheva. „RADIATION SITUATION ON THE TERRITORY OF THE NORTHERN SLOPES OF THE TURKESTAN RIDGE“. In SAKHAROV READINGS 2022: ENVIRONMENTAL PROBLEMS OF THE XXI CENTURY. International Sakharov Environmental Institute of Belarusian State University, 2022. http://dx.doi.org/10.46646/sakh-2022-2-261-265.

Der volle Inhalt der Quelle
Annotation:
The article presents the results of radiation monitoring on the territory of the northern slopes of the Turkestan ridge. It is shown that the total specific activity is less than 1 Bq/g. The specific activities of the soil taken from the sites of Obi Zulol Street is equal to - 0,82 Bq/g, and of the drainage ditch of the Firdavsi village of Shakhristan district - 0,78 Bq/g. Anomalous specific activity is observed in samples numbered 3-6. This is due to the activities of the actinium-227.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Rattyananda, Badra Sanditya, Duyeh Setiawan, Muhamad Basit Febrian, Rasito Tursinah, Rudi Gunawan, Teguh Hafiz Ambar Wibawa, Yanuar Setiadi, Isa Mahendra und Ahmad Kurniawan. „Preliminary study of radioisotopes Actinium-225 (225Ac) production using Indonesian DECY-13 cyclotron conceptual design“. In INTERNATIONAL CONFERENCE ON NUCLEAR SCIENCE, TECHNOLOGY, AND APPLICATIONS – ICONSTA 2022. AIP Publishing, 2024. http://dx.doi.org/10.1063/5.0193405.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Waldek, Achim. „RIMS measurements for the determination of the first ionization potential of the actinides actinium up to einsteinium“. In RESONANCE IONIZATION SPECTROSCOPY 2000: Laser Ionization and Applications Incorporating RIS; 10th International Symposium. AIP, 2001. http://dx.doi.org/10.1063/1.1405607.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen

Berichte der Organisationen zum Thema "Actinium"

1

Brown, M. Developing Inorganic Resins for Radium and Actinium Generators and Purifications. Office of Scientific and Technical Information (OSTI), Dezember 2022. http://dx.doi.org/10.2172/1908454.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
2

Haring, M. M. Report for General Research April 1 to July 26, 1950 (Actinium Volume). Office of Scientific and Technical Information (OSTI), Juli 2009. http://dx.doi.org/10.2172/958402.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
3

Harvey, James T., Jerry Nolen, George Vandergrift, Itacil Gomes, Tom Kroc, Phil Horwitz, Dan McAlister, Del Bowers, Vivian Sullivan und John Greene. Production of Actinium-225 via High Energy Proton Induced Spallation of Thorium-232. Office of Scientific and Technical Information (OSTI), Dezember 2011. http://dx.doi.org/10.2172/1032445.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
4

Noguere, Gilles, Oscar Cabellos, Denise Neudecker, Andrej Trkov und Roberto Capote Noy. Summary Report of the IAEA Consultants’ Meeting of the International Nuclear Data Evaluation Network (INDEN) on Actinide Evaluation in the Resonance Region (4). IAEA Nuclear Data Section, September 2022. http://dx.doi.org/10.61092/iaea.kw6h-tcge.

Der volle Inhalt der Quelle
Annotation:
A Consultants’ Meeting on Actinide Evaluation in the Resonance Region (4) of the International Nuclear Data Evaluation Network (INDEN) was held as a hybrid meeting from 1 to 4 November 2021. The meeting was a follow-up of the working group on evaluations in the resonance region of actinide nuclei. On-going evaluation work on 233U, 238U, 235U and 239Pu was discussed. Particular attention was paid to Prompt Fission Neutron Spectra, neutron multiplicities and reference integrals for fission cross sections were proposed for TOF fission data of fissile targets.
APA, Harvard, Vancouver, ISO und andere Zitierweisen
5

Migliori, Albert. Actinide Research Quarterly. Office of Scientific and Technical Information (OSTI), Juni 2015. http://dx.doi.org/10.2172/1188164.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
6

Stoyer, Nancy Jane. Actinide cation-cation complexes. Office of Scientific and Technical Information (OSTI), Dezember 1994. http://dx.doi.org/10.2172/34204.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
7

Choppin, G. R. Research in actinide chemistry. Office of Scientific and Technical Information (OSTI), Januar 1993. http://dx.doi.org/10.2172/6735291.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
8

Koenig, Z. M., W. D. Ruhter und R. Gunnink. Actinide isotopic analysis systems. Office of Scientific and Technical Information (OSTI), Oktober 1990. http://dx.doi.org/10.2172/6447881.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
9

Browne, Kevin Patrick. Actinide High-Nitrogen Chemistry. Office of Scientific and Technical Information (OSTI), Mai 2015. http://dx.doi.org/10.2172/1179259.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
10

Shehee, T. C. 2013 Actinide Separation conference Presentations on Minor Actinide Separations by SRNL Participants (Shehee). Office of Scientific and Technical Information (OSTI), Juni 2013. http://dx.doi.org/10.2172/1553555.

Der volle Inhalt der Quelle
APA, Harvard, Vancouver, ISO und andere Zitierweisen
Die Auswahlen zum Thema "Actinium" für konkrete Quellenarten können Sie auch interessieren:
Zeitschriftenartikel Dissertationen Bücher
Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!

Zur Bibliographie